Repare Therapeutics Agrees to $1.82 Per Share Acquisition by XenoTherapeutics
核心洞察
Repare Therapeutics has entered into a definitive agreement to be acquired by non-profit biotechnology company XenoTherapeutics (搜索) for an estimated $1.82 per share plus contingent value rights.
Shareholders will receive additional payments through CVRs tied to existing partnerships with Bristol-Myers Squibb (搜索), Debiopharm (搜索), and DCx Biotherapeutics (搜索), with percentages ranging from 75% to 100% over 10 years.
The transaction is expected to close in the first quarter of 2026, subject to shareholder approval and court approval under Quebec's Business Corporations Act.
Repare Therapeutics Inc., a clinical-stage precision oncology company, announced it has entered into a definitive arrangement agreement with XenoTherapeutics (搜索), Inc. and Xeno Acquisition Corp., a non-profit biotechnology company, for the acquisition of all outstanding common shares of Repare.
Under the terms of the agreement, Repare shareholders will receive a cash payment per share determined by Repare's cash balance at closing after deducting transaction costs and outstanding liabilities. Based on current estimates, each shareholder is expected to receive $1.82 per common share at closing.
Contingent Value Rights Structure
In addition to the upfront cash payment, shareholders will receive one non-transferable contingent value right (CVR) for each common share. These CVRs entitle holders to receive cash payments from multiple sources:
- 100% of additional receivables received within 90 days following closing
- Percentage-based payments from existing partnerships with Bristol-Myers Squibb, Debiopharm, and DCx Biotherapeutics: 90% for the first two years, declining to 85% for years 2-4, 80% for years 4-6, and 75% for years 6-10
- 100% of net proceeds from licensing or disposition of RP-1664, RP-3500 (Camonsertib), or other programs if agreements are entered before closing
- 100% of net proceeds from Polθ program RP-3467 licensing to parties with whom negotiations began before closing
- 50% of net proceeds from any other licensing or disposition occurring within 10 years after closing
Transaction Timeline and Approval Process
The transaction will be implemented through a court-approved plan of arrangement under Quebec's Business Corporations Act. It requires approval from at least 66⅔% of votes cast by Repare shareholders and a majority excluding certain "interested parties" as required by Multilateral Instrument 61-101.
The transaction is expected to close in the first quarter of 2026, subject to shareholder approval, Superior Court of Quebec approval, and other customary closing conditions.
Board Recommendation and Deal Protection
A transaction committee composed entirely of independent directors unanimously recommended the arrangement to Repare's Board of Directors. The Board has unanimously approved the transaction and will recommend shareholders vote in favor at the special meeting.
The agreement includes customary deal-protection provisions, including a non-solicitation covenant and a right for Xeno to match any superior proposal. A termination fee of $2.0 million is payable by Repare under certain circumstances, including if the company enters into a definitive agreement for a superior proposal.
Clinical Pipeline Update
Repare recently presented positive initial safety, tolerability, and early efficacy data from its Phase 1 LIONS clinical trial evaluating RP-1664 as monotherapy in adult and adolescent patients with TRIM37 (搜索)-high solid tumors (搜索) at the 37th AACR-NCI-EORTC International Conference. The data support further investigation of PLK4 (搜索) inhibition as a therapeutic modality, particularly in less pretreated patients.
As a result of the definitive agreement, Repare will no longer report initial topline data from the POLAR trial evaluating RP-3467 in monotherapy and combination with Olaparib.
Financial Position
As of September 30, 2025, Repare reported $112.6 million in cash, cash equivalents, and marketable securities, compared to $109.5 million at June 30, 2025. For the third quarter of 2025, the company reported revenue from collaboration agreements of $11.6 million and net research and development expenses of $7.5 million.
Post-Transaction Structure
Following completion, Repare will become a privately held company, with common shares expected to be delisted from the Nasdaq Global Select Market. The company will also apply to cease being a reporting issuer under Canadian securities laws and to deregister shares under the U.S. Securities Exchange Act.
"Following a thorough and wide-ranging strategic review of potential opportunities, partnerships and transactions aimed at maximizing shareholder value, Repare's Board of Directors has unanimously determined that the Transaction is in the best interests of Repare and its various stakeholders," said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare.